Citi analyst Joanne Wuensch lowered the firm’s price target on Haemonetics (HAE) to $64 from $70 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology group as part of a Q1 preview. The “walls of worry are high” into the earnings reports with the sector undergoing significant multiple compression, the analyst tells investors in a research note. Citi removed iRhythm and Medtronic as top picks. The firm’s top picks are now Edwards Lifesciences and Intuitive Surgical.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics: FDA Label Expansion and New Product Launches Poised to Reignite Vascular Closure Growth by FY27
- Haemonetics: FDA approves expanded labeling for VASCADE MVP XL system
- Haemonetics price target lowered to $70 from $75 at Citi
- Haemonetics Retires 2026 Convertible Notes, Simplifies Capital Structure
- Haemonetics receives FDA clearance for NexSys PCS Plasma Collection System